Summit Therapeutics Announces Q1 2026 Financial Results and Highlights Key Operational Achievements
Summit Therapeutics Inc. (NASDAQ: SMMT) has reported its financial results for the first quarter ended March 31, 2026, while also providing a comprehensive update on its clinical pipeline and operational progress. The company’s strategy continues to center on the advancement of ivonescimab (SMT112), a novel investigational bispecific antibody that integrates immunotherapy and anti-angiogenic mechanisms into a single therapeutic approach.
Advancing a Potential First-in-Class Bispecific Antibody
Ivonescimab represents a differentiated approach to cancer treatment by simultaneously targeting two critical biological pathways: programmed cell death protein 1 (PD-1), a key immune checkpoint, and vascular endothelial growth factor (VEGF), which plays a central role in tumor angiogenesis. By combining PD-1 inhibition with VEGF blockade in one molecule, ivonescimab is designed to enhance anti-tumor immune responses while also disrupting the tumor’s blood supply.
Since Summit in-licensed ivonescimab from Akeso Inc. in January 2023, the therapy has gained significant clinical and commercial exposure. More than 4,000 patients have been treated with ivonescimab in clinical trials worldwide, while over 70,000 patients have received the drug in a commercial setting in China, based on updates provided by Akeso. Under the terms of the agreement, Summit holds rights to develop and commercialize ivonescimab across major global markets, including North America, Europe, South America, the Middle East, Africa, and Japan, while Akeso retains rights in China and certain other regions.
Expanding a Broad Phase III Clinical Program
Summit is advancing ivonescimab through an extensive global Phase III clinical development program, with a primary focus on non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). Several pivotal studies are currently underway under the HARMONi clinical trial series.
Among these, the HARMONi trial is evaluating ivonescimab in combination with chemotherapy for patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have previously been treated with third-generation EGFR tyrosine kinase inhibitors (TKIs). This study has already supported a regulatory submission, marking a significant milestone for the program.
The HARMONi-3 trial is investigating ivonescimab plus chemotherapy as a first-line treatment for metastatic NSCLC. The study includes two distinct cohorts—squamous and non-squamous tumors—which will be analyzed separately. In the squamous cohort, an interim progression-free survival (PFS) analysis was conducted in early 2026 and reviewed by an independent data monitoring committee (iDMC). The committee recommended that the study continue as planned, with no safety concerns identified. Importantly, the trial remains double-blinded, and the company has reiterated that the final PFS analysis is still expected in the second half of 2026.
For the non-squamous cohort of HARMONi-3, patient enrollment is progressing steadily and is now anticipated to be completed by the end of the second quarter of 2026. Summit expects to report PFS data for this group in the first half of 2027.
Additional Phase III trials include HARMONi-7, which is evaluating ivonescimab as a monotherapy in patients with high PD-L1-expressing metastatic NSCLC, and HARMONi-GI3, which is exploring its use in combination with chemotherapy for first-line treatment of unresectable metastatic colorectal cancer.
Upcoming Data Presentation at ASCO 2026
A major near-term catalyst for the ivonescimab program will be the presentation of overall survival data from the Phase III HARMONi-6 trial at the American Society of Clinical Oncology Annual Meeting 2026. This study, conducted in China and sponsored by Akeso, evaluated ivonescimab in combination with platinum-based chemotherapy versus tislelizumab plus chemotherapy in patients with locally advanced or metastatic squamous NSCLC, regardless of PD-L1 expression.
The results have been selected for presentation in the prestigious Plenary Session, underscoring their potential significance. Late-breaking data from the study are scheduled to be released on May 31, 2026, and could provide important insights into ivonescimab’s comparative efficacy in a highly competitive treatment landscape.
Strategic Collaborations to Broaden Clinical Impact
Beyond its internally sponsored trials, Summit is actively expanding ivonescimab’s development through multiple strategic collaborations. In partnership with Revolution Medicines, Inc., the company is evaluating ivonescimab in combination with a portfolio of RAS(ON) inhibitors, including daraxonrasib (RMC-6236), zoldonrasib (RMC-9805), and elironrasib (RMC-6291). These studies aim to address solid tumors driven by RAS mutations, a historically challenging target in oncology. The first trial under this collaboration began enrolling patients in early 2026.
Summit has also entered into a collaboration with GSK plc to investigate ivonescimab in combination with GSK’s B7-H3-targeting antibody-drug conjugate, risvutatug rezetecan. This study is expected to begin dosing patients in mid-2026 and reflects a growing interest in combination strategies that leverage complementary mechanisms of action.
In Europe, Summit is working with GORTEC on a Phase III trial known as ILLUMINE (GORTEC 2024-04). This study will compare ivonescimab-based regimens—both as monotherapy and in combination with ligufalimab, an anti-CD47 antibody—against pembrolizumab in patients with PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma. The trial is expected to enroll approximately 780 patients across multiple countries, with enrollment anticipated to begin in the second quarter of 2026.
Additionally, investigator-sponsored trials (ISTs) are playing a significant role in expanding ivonescimab’s clinical footprint. Collaborations with leading academic institutions such as MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Dana-Farber Cancer Institute are supporting more than 65 studies, with 20 currently enrolling patients. These efforts are helping to explore ivonescimab’s potential across a wide range of tumor types.
Financial Performance Reflects Expanding Development Efforts
From a financial perspective, Summit reported cash, cash equivalents, and short-term investments totaling $598.7 million as of March 31, 2026, compared to $713.4 million at the end of 2025. The decrease reflects continued investment in clinical development and operational expansion.
GAAP operating expenses for the first quarter of 2026 rose significantly to $195.2 million, compared to $66.8 million in the same period of 2025. This increase was largely driven by higher stock-based compensation expenses, particularly related to modifications of performance-based stock option awards made in 2025.
On a non-GAAP basis, operating expenses were $122.4 million, up from $55.7 million in the prior year period. The growth in expenses was primarily attributable to the expansion of clinical trials and increased development activity surrounding ivonescimab.
Research and development (R&D) expenses also saw a notable rise. GAAP R&D expenses reached $132.6 million, compared to $51.2 million in the first quarter of 2025, while non-GAAP R&D expenses increased to $108.2 million from $47.1 million. These increases reflect the initiation of new studies and the scaling of ongoing trials.
General and administrative (G&A) expenses followed a similar trend. GAAP G&A expenses were $62.6 million, up from $15.6 million in the prior year, largely due to stock-based compensation. Non-GAAP G&A expenses rose to $14.2 million from $8.6 million, driven by infrastructure expansion and organizational growth.
Summit reported a GAAP net loss of $189.4 million for the quarter, or $(0.24) per share, compared to a net loss of $62.9 million, or $(0.09) per share, in the same period of 2025. On a non-GAAP basis, net loss was $116.6 million, or $(0.15) per share, compared to $51.8 million, or $(0.07) per share, in the prior year.
Summit plans to continue expanding its global Phase III development program for ivonescimab into additional tumor types beyond NSCLC, colorectal cancer, and head and neck cancers. The company has indicated that further details regarding new studies will be shared in the coming months.
To discuss these updates and the anticipated data from ASCO 2026, Summit will host a conference call on June 1, 2026, following the plenary presentation. The webcast will be accessible via the company’s website, with an archived version available afterward.
Overall, Summit’s first-quarter update highlights a company in rapid expansion mode, with significant investments in clinical development and a growing body of data supporting its lead asset. As ivonescimab progresses through late-stage trials and approaches potential regulatory milestones, the coming months are expected to be pivotal in defining its role in the evolving oncology treatment landscape.
Source Link:https://www.businesswire.com/
